GSEP
BMRN icon

Golden State Equity Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Golden State Equity Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-324
Closed -$22.8K – 498
2024
Q3 		$22.8K Buy
+324
New +$27.1K 0.01% 497

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Golden State Equity Partners's BMRN Position: Q4 2024 in Review

Golden State Equity Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 324 shares — an estimated $22.8K sold.

Golden State Equity Partners first reported a position in BMRN in Q3 2024 and held it in 1 quarter. The position peaked at $22.8K in Q3 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Golden State Equity Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 324 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $22.8K.
  • Golden State Equity Partners first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Golden State Equity Partners's BioMarin Pharmaceuticals position peaked at $22.8K in Q3 2024.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.